Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Subscribe To Our Newsletter & Stay Updated
